Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54,731,500
-
Total 13F shares
-
29,901,506
-
Share change
-
-1,855,939
-
Total reported value
-
$355,397,830
-
Put/Call ratio
-
130%
-
Price per share
-
$11.88
-
Number of holders
-
71
-
Value change
-
-$20,740,705
-
Number of buys
-
28
-
Number of sells
-
36
Institutional Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q4 2021
As of 31 Dec 2021,
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) was held by
71 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,901,506 shares.
The largest 10 holders included
Lion Point Capital, LP, Avoro Capital Advisors LLC, BlackRock Inc., VR Adviser, LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, 683 Capital Management, LLC, VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., and Bleichroeder LP.
This page lists
70
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.